NCT06061874 Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis
| NCT ID | NCT06061874 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jules Bordet Institute |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-05-30 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-05-30 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein). The aim of the study is to assess the accuracy of Ga68-FAPI-46 PET/CT for preoperative assessment of peritoneal carcinomatosis in colorectal and ovarian cancer.
Eligibility Criteria
Inclusion Criteria: * Histologically proven colorectal and ovarian cancer. * Known or suspected peritoneal metastases from the tumour of origin. * Scheduled for peritoneal complete cytoreductive surgery with curative intent with or without neoadjuvant chemotherapy. * ECOG (Eastern Cooperative Oncology Group) Performance status ≤2. * Signed written informed consent obtained before any study-specific screening procedures. Exclusion Criteria: * Non-resectable extra-abdominal metastasis and/or \>3 hepatic metastases on standard work-up * Known chronic inflammatory conditions including the intestinal system (eg. inflammatory bowel disease, Crohn's disease) * Pregnant and lactating women * Previous or concurrent malignancy diagnosed within the last 3 years except adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell skin cancer. * Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Contact & Investigator
Patrick Flamen
PRINCIPAL INVESTIGATOR
Jules Bordet Institute
Frequently Asked Questions
Who can join the NCT06061874 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06061874 currently recruiting?
Yes, NCT06061874 is actively recruiting participants. Contact the research team at loubna.taraji@hubruxelles.be for enrollment information.
Where is the NCT06061874 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT06061874 clinical trial?
NCT06061874 is sponsored by Jules Bordet Institute. The principal investigator is Patrick Flamen at Jules Bordet Institute. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.